Drug intelligence / Profile preview

galicaftor + ABBV-576

Development stage: Unknown
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

**galicaftor + ABBV-576** is an investigational triple combination therapy for the treatment of cystic fibrosis, specifically targeting patients who are homozygous or heterozygous for the F508del mutation in CFTR. Galicaftor and ABBV-576 are both small molecule cystic fibrosis transmembrane conductance regulator (CFTR) modulators, designed to improve the function of defective CFTR protein caused by genetic mutations. Clinical trials are evaluating this combination as a once-daily oral therapy for cystic fibrosis. Galicaftor is also known as ABBV-2222, and ABBV-576 is a discrete CFTR modulator developed by AbbVie[1][2][3][4][5][6].

Other names: galicaftor + ABBV-576

Targets

CFTR (Cystic fibrosis transmembrane conductance regulator)

Beyond the preview

Go deeper on galicaftor + ABBV-576.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on galicaftor + ABBV-576.

Explore the full profile